Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.
Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.
